Navidea Biopharmaceuticals (NAVB) Competitors $0.0007 0.00 (0.00%) As of 05/21/2025 03:50 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsOptions ChainSEC FilingsTrendsBuy This Stock NAVB vs. TCBP, NCNA, UPC, VINC, HSTO, ADTX, PLRZ, SCPS, EVLO, and GNCAQShould you be buying Navidea Biopharmaceuticals stock or one of its competitors? The main competitors of Navidea Biopharmaceuticals include TC Biopharm (TCBP), NuCana (NCNA), Universe Pharmaceuticals (UPC), Vincerx Pharma (VINC), Histogen (HSTO), Aditxt (ADTX), Polyrizon (PLRZ), Scopus BioPharma (SCPS), Evelo Biosciences (EVLO), and Genocea Biosciences (GNCAQ). These companies are all part of the "pharmaceutical products" industry. Navidea Biopharmaceuticals vs. TC Biopharm NuCana Universe Pharmaceuticals Vincerx Pharma Histogen Aditxt Polyrizon Scopus BioPharma Evelo Biosciences Genocea Biosciences TC Biopharm (NASDAQ:TCBP) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, community ranking, media sentiment, institutional ownership and valuation. Do institutionals and insiders hold more shares of TCBP or NAVB? 16.3% of TC Biopharm shares are owned by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. 15.4% of TC Biopharm shares are owned by insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has preferable valuation and earnings, TCBP or NAVB? TC Biopharm has higher revenue and earnings than Navidea Biopharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTC Biopharm$4.76M0.06-$7.35MN/AN/ANavidea Biopharmaceuticals$8.13K8.62-$15.18MN/AN/A Does the MarketBeat Community believe in TCBP or NAVB? TC Biopharm received 2 more outperform votes than Navidea Biopharmaceuticals when rated by MarketBeat users. Likewise, 66.67% of users gave TC Biopharm an outperform vote while only 0.00% of users gave Navidea Biopharmaceuticals an outperform vote. CompanyUnderperformOutperformTC BiopharmOutperform Votes266.67% Underperform Votes133.33% Navidea BiopharmaceuticalsOutperform VotesNo VotesUnderperform Votes87100.00% Does the media favor TCBP or NAVB? In the previous week, Navidea Biopharmaceuticals had 1 more articles in the media than TC Biopharm. MarketBeat recorded 1 mentions for Navidea Biopharmaceuticals and 0 mentions for TC Biopharm. TC Biopharm's average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score. Company Overall Sentiment TC Biopharm Neutral Navidea Biopharmaceuticals Neutral Which has more volatility & risk, TCBP or NAVB? TC Biopharm has a beta of 0.01, indicating that its stock price is 99% less volatile than the S&P 500. Comparatively, Navidea Biopharmaceuticals has a beta of 2.21, indicating that its stock price is 121% more volatile than the S&P 500. Is TCBP or NAVB more profitable? Company Net Margins Return on Equity Return on Assets TC BiopharmN/A N/A N/A Navidea Biopharmaceuticals N/A N/A N/A Do analysts rate TCBP or NAVB? TC Biopharm presently has a consensus price target of $48.00, suggesting a potential upside of 6,948.46%. Given TC Biopharm's stronger consensus rating and higher possible upside, equities analysts plainly believe TC Biopharm is more favorable than Navidea Biopharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TC Biopharm 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Navidea Biopharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryTC Biopharm beats Navidea Biopharmaceuticals on 8 of the 12 factors compared between the two stocks. Get Navidea Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NAVB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NAVB vs. The Competition Export to ExcelMetricNavidea BiopharmaceuticalsDiagnostic substances IndustryMedical SectorNYSE ExchangeMarket Cap$70,000.00$2.61B$5.31B$19.25BDividend YieldN/A0.73%5.21%3.83%P/E RatioN/A7.4226.7834.49Price / Sales8.6235.72386.9734.66Price / CashN/A15.7538.2517.51Price / BookN/A5.546.744.67Net Income-$15.18M-$65.73M$3.23B$1.02B7 Day PerformanceN/A0.21%1.49%-2.14%1 Month PerformanceN/A3.01%11.47%7.04%1 Year PerformanceN/A-15.81%16.57%3.72% Navidea Biopharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NAVBNavidea BiopharmaceuticalsN/A$0.00flatN/A-97.7%$70,000.00$8,126.000.0010News CoverageTCBPTC Biopharm1.2267 of 5 stars$0.68-55.8%$48.00+6,948.5%-99.6%$279,000.00$4.76M0.0080High Trading VolumeNCNANuCana2.2093 of 5 stars$0.05+10.0%$25.00+51,767.2%-98.9%$274,000.00N/A0.0030High Trading VolumeUPCUniverse PharmaceuticalsN/A$6.29+14.6%N/A-99.6%$270,000.00$23.02M0.00220Gap UpVINCVincerx Pharma2.4371 of 5 stars$0.05-12.5%$40.00+83,060.1%-99.7%$252,000.00N/A0.0060Gap DownHSTOHistogenN/A$0.03flatN/A-81.7%$133,000.00$19,000.00-0.0120ADTXAditxt0.8632 of 5 stars$1.75+5.4%N/A-100.0%$100,000.00$133,985.000.0060Positive NewsEarnings ReportGap UpPLRZPolyrizonN/A$0.01flatN/AN/A$28,000.00N/A0.00N/ANews CoveragePositive NewsGap UpHigh Trading VolumeSCPSScopus BioPharmaN/A$0.00flatN/AN/A$13,000.00N/A0.009EVLOEvelo BiosciencesN/A$0.00+66.7%N/AN/A$9,000.00N/A0.00120High Trading VolumeGNCAQGenocea BiosciencesN/AN/AN/AN/A$6,000.00N/A0.0070 Related Companies and Tools Related Companies TC Biopharm Competitors NuCana Competitors Universe Pharmaceuticals Competitors Vincerx Pharma Competitors Histogen Competitors Aditxt Competitors Polyrizon Competitors Scopus BioPharma Competitors Evelo Biosciences Competitors Genocea Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:NAVB) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Navidea Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Navidea Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NAVB Stock Free NAVB Stock Alerts